FDA Investigator Karen Takahashi

Karen Takahashi has conducted inspections on 28 sites in 14 countries as of 05 Sep 2011. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
28
Last Inspection Date:
05 Sep 2011
Investigator Role:
FDA Investigation Participant
Redica ID:
100003674
Countries of Inspections:
Denmark, Norway, Japan, France, India, Italy, Spain, Germany, United Kingdom of Great Britain and Northern Ireland, China, South Africa, Macao, Taiwan, Ireland
FDA Investigators that have inspected at least one site in common with Karen Takahashi:
Albinus M D'sa, Alicia M Mozzachio, Andrea A Branche, Angela E Glenn, Anita Narula, PhD, Ann L Demarco, Anthony A Charity, Ariel Cruz Figueroa, Arsen Karapetyan, Atul J Agrawal, Azza Talaat, Barbara M Frazier, Bernice F Hirsch, CDR Rochelle B Young, RPh, MSA, Charles R Cote, RIC, Christopher T Middendorf, Cynthia J Lee, MS, Daniel W Cline, Dennis Cantellops Paite, Devaughn Edwards, Dipesh K Shah, Djamila Harouaka, Dr. Carmelo Rosa, Dr. Chunchang Fang, Dr. Robert C Horan, MD, Dr. S Nar Ali, PhD, Elizabeth D Connell, Erika V Butler, Felix Maldonado, Geneve M Maxwell, Geneve M Parks, Gerardo Z Vazquez, Ivis L Negron, James L Dunnie, Jr, James S Cartwright, Jawaid Hamid, Jennifer Lalama, Jessica L Pressley, Joanne E King, John A Gonzalez, John M Dietrick, Jose A Lopez, Jose R Hernandez, Junho Pak, Justin A Boyd, Justine Tomasso, Kara D Dobbin, Karen K Moksnes, Katherine Szestypalow, Kenneth H Williams, Kent C Faul, Kevin P Foley, Kham Phommachanh, Kim Lthomas Cruse, Kristen D Evans, Laurie B Frazier, Lawrence Harmon, Jr, Liang Zhou, Lisa M Bellows, Lisa M Feola, Lucas B Leake, Mary E Storch, Matthew B Casale, Michael A Charles, Michele Perry Williams, Mra Davism, Mra Mcculloughj, Muralidhara B Gavini, PhD, Nalini D Lebzelter, Pankaj H Amin, Parul M Patel, Patsy J Domingo, Penny H Mccarver, Peter E Baker, Qin Xu, Ralph H Vocque, Regina T Brown, Richard H Penta, Robert C Coleman, Robert D Tollefsen, Rochelle K Kimmel, Rochelle L Cross, Roy R Rinc, Rumany C Penn, PharmD, Saied A Asbagh, Samantha J Bradley, Samuel T Walker, Sandra A Hughes, Sangeeta M Khurana, PhD, Sarah M Meng, Sarah M Napier, Satheesh Thomas, Sonya M Edmonds, Stacie A Woods, Stephen D Brown, Steven B Hertz, Steven D Kehoe, Susan F Laska, MS, Susan W Ting, Syed N Ali, Terri L Dodds, Thomas E Friel, Tiffani D Wilson, Timothy T Kapsala, Truong Xuan Nguyen (Andy), Vlada Matusovsky, William J Leonard, Yumi J Hiramine, Zachary L Miller

Karen Takahashi's Documents

Publish Date Document Type Title
October, 2003 EIR Morepen Laboratories Limited - EIR, 2004-02-10
November, 2003 EIR FDC Limited - EIR, 2004-01-22
May, 2004 EIR Steins Laboratorium A/S - EIR, 2004-06-30
November, 2003 FDA 483 FDC Limited - Form 483, 2003-11-12
November, 2004 FDA 483 Hovione Pharmascience Limited - Form 483, 2004-11-03
October, 2003 FDA 483 Response Morepen Laboratories Limited - Form 483R, 2004-02-11
June, 2004 FDA 483 Response Fertin Pharma A/S - Form 483R, 2004-06-26
May, 2002 EIR Huzhou Zhanwang Pharmaceutical Co., Ltd. - EIR, 2002-07-15
June, 2004 EIR Fertin Pharma A/S - EIR, 2004-07-13
May, 2004 FDA 483 Response Steins Laboratorium A/S - Form 483R, 2004-06-24
November, 2003 FDA 483 Response FDC Limited - Form 483R, 2003-12-31
November, 2003 FDA 483 Sun Pharmaceutical Industries Limited - Form 483, 2003-11-06
June, 2004 FDA 483 Response Fertin Pharma A/s - Form 483R, 2004-07-26
November, 2003 FDA 483 Response Sun Pharmaceutical Industries Limited - Form 483R, 2003-12-05
November, 2003 EIR Sun Pharmaceutical Industries Limited - EIR, 2004-01-22
May, 2002 FDA 483 Response Star Lake Bioscience Co., Inc. Zhaoqing Guangdong Star Lake Bio-chemical Pharmaceutical Factory - Form 483R, 2002-05-09
May, 2002 FDA 483 Response Huzhou Zhanwang Pharmaceutical Co., Ltd. - Form 483R, 2002-06-21
May, 2004 FDA 483 Steins Laboratorium A/S - Form 483, 2004-05-25
May, 2002 EIR Star Lake Bioscience Co., Inc. Zhaoqing Guangdong Star Lake Bio-chemical Pharmaceutical Factory - EIR, 2002-07-01
June, 2004 EIR Fertin Pharma A/s - EIR, 2004-07-14

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more